Jefferson Parker

Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.

M Krámer, J. Hermans, Jefferson Parker et al. · Journal of Clinical Oncology · 1996 · 205 citations

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

Yasuhiro Oki, Kevin R. Kelly, Ian W. Flinn et al. · Haematologica · 2017 · 130 citations · Full text

Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses

Daniel J. Landsburg, Stefan K. Barta, Radhakrishnan Ramchandren et al. · British Journal of Haematology · 2021 · 42 citations · Full text

Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell Transplant

Jon Arnason, Katarina Luptakova, Jacalyn Rosenblatt et al. · Acta Haematologica · 2015 · 11 citations

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Robert N. Booher, Grzegorz S. Nowakowski, Krish Patel et al. · Blood · 2018 · 10 citations